1. |
Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and prevalence of childhood epilepsy: A nationwide cohort study. Pediatrics, 2017, 139(5): 1-9.
|
2. |
Ghani S, Vilensky J, Turner B, et al. Meta-analysis of vagus nerve stimulation treatment for epilepsy: correlation between device setting parameters and acute response. Childs Nerv Syst, 2015, 31(12): 2291-2304.
|
3. |
Johnson R, Wilson C. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res, 2018, 11: 203-213.
|
4. |
中国医师协会神经内科分会癫痫专委会. 迷走神经刺激术治疗癫(癎)的中国专家共识. 中国医师杂志, 2015, 7(17): 967-968.
|
5. |
FDA. PMA Monthly approvals List [EB/OL]. https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/UCM565765.pdf. Published 2017. Updated 03/03/2019 03: 39. Accessed 2, 2019: 5-17.
|
6. |
Revesz D, Frojd V, Rydenhag B, et al. Estimating long-term vagus nerve stimulation effectiveness: Accounting for antiepileptic drug treatment changes. Neuromodulation, 2018, 21(8): 797-804.
|
7. |
George L. Morris III DG, Jeffrey Buchhalter, et al Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy report of the guideline development subcommittee of the American academy of neurology. American Academy of Neurology, 2013, 81: 1453-1459.
|
8. |
Lagae L, Verstrepen A, Nada A, et al. Vagus nerve stimulation in children with drug-resistant epilepsy: age at implantation and shorter duration of epilepsy as predictors of better efficacy? Epileptic Disord, 2015, 17(3): 308-314.
|
9. |
Ji T, Yang Z, Liu Q, et al. Vagus nerve stimulation for pediatric patients with intractable epilepsy between 3 and 6 years of age: study protocol for a double-blind, randomized control trial. Trials, 2019, 20(1): 44-54.
|
10. |
Orosz I, McCormick D, Zamponi N, et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia, 2014, 55(10): 1576-1584.
|
11. |
Kavcic A, Kajdic N, Rener-Primec Z, et al. Efficacy and tolerability of vagus nerve stimulation therapy (VNS) in Slovenian epilepsy patients: younger age and shorter duration of epilepsy might result in better outcome. Acta Clin Croat, 2019, 58(2): 255-264.
|
12. |
Pindrik J, Hoang N, Smith L, et al. Preoperative evaluation and surgical management of infants and toddlers with drug-resistant epilepsy. Neurosurg Focus, 2018, 45(3): 3-6.
|
13. |
Moro-De Faes G, Serrano-Moyano B, Cantarin-Extremera V, et al. Ten years' experience with vagus nerve stimulation in a paediatric population. Rev Neurol, 2018, 67(10): 382-386.
|
14. |
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia, 2017, 58(4): 512-521.
|
15. |
Fulton SP, Van Poppel K, McGregor AL, et al. Vagus nerve stimulation in intractable epilepsy associated with SCN1A gene abnormalities. J Child Neurol, 2017, 32(5): 494-498.
|
16. |
Lim Z, Wong K, Downs J, et al. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 deficiency disorder. Epilepsy research, 2018, 146: 36-40.
|
17. |
Syvertsen M, Hellum MK, Hansen G, et al. Prevalence of juvenile myoclonic epilepsy in people <30 years of age-A population-based study in Norway. Epilepsia, 2017, 58(1): 105-112.
|
18. |
Kostov H, Larsson P, Røste G. Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy? Acta neurologica Scandinavica Supplementum, 2007, 187: 55-58.
|
19. |
Parain D, Penniello M, Berquen P, et al. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatric neurology, 2001, 25(3): 213-216.
|
20. |
Grioni D, Landi A. Does vagal nerve stimulation treat drug-resistant epilepsy in patients with tuberous sclerosis complex? World Neurosurg, 2019, 121: 251-253.
|
21. |
Cersosimo RO, Bartuluchi M, Fortini S, et al. Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies. Epileptic Disord, 2011, 13(4): 382-388.
|
22. |
Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci, 2018, 39(3): 403-414.
|
23. |
Cukiert A, Cukiert CM, Burattini JA, et al. Long-term outcome after callosotomy or vagus nerve stimulation in consecutive prospective cohorts of children with Lennox-Gastaut or Lennox-like syndrome and non-specific MRI findings. Seizure, 2013, 22(5): 396-400.
|
24. |
Tao JX, Satzer D, Issa NP, et al. Stereotactic laser anterior corpus callosotomy for Lennox-Gastaut syndrome. Epilepsia, 2020, 61(6): 1190-1200.
|
25. |
Zamponi N, Passamonti C, Cesaroni E, et al. Effectiveness of vagal nerve stimulation (VNS) in patients with drop-attacks and different epileptic syndromes. Seizure, 2011, 20(6): 468-474.
|
26. |
Dibue-Adjei M, Fischer I, Steiger HJ, et al. Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: A meta-analysis of 68 patients. Seizure, 2017, 50: 147-152.
|
27. |
Ali R, Elsayed M, Kaur M, et al. Use of social media to assess the effectiveness of vagal nerve stimulation in Dravet syndrome: A caregiver's perspective. J Neurol Sci, 2017, 375: 146-149.
|
28. |
You SJ, Kang HC, Ko TS, et al. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox-Gastaut syndrome. Brain Dev, 2008, 30(3): 195-199.
|
29. |
Wang AJ, Bick SK, Williams ZM. Vagus nerve stimulation versus responsive neurostimulator system in patients with temporal lobe epilepsy. Stereotact Funct Neurosurg, 2020, 98(1): 21-29.
|
30. |
Ryzi M, Brazdil M, Novak Z, et al. Long-term outcomes in patients after epilepsy surgery failure. Epilepsy Res, 2015, 110: 71-77.
|
31. |
Ohemeng KK, Parham K. Vagal nerve stimulation: indications, implantation, and outcomes. Otolaryngol Clin North Am, 2020, 53(1): 127-143.
|
32. |
Parhizgar F, Nugent K, Raj R. Obstructive sleep apnea and respiratory complications associated with vagus nerve stimulators. Journal of clinical sleep medicine, 2011, 7(4): 401-407.
|